A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

NCT07191483 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Impairment Associated With Schizophrenia (CIAS)

Interventions

DRUG: KYN-5356 low dose
OTHER: Placebo
DRUG: KYN-5356 Medium Dose
DRUG: KYN-5356 High Dose

Sponsor

Kynexis B.V.